🕒 Last update: loading…

Stock Organigram Global Inc. OGI.TO

Organigram Global Inc. — Investlytic score 2/5 on the five criteria.

-
-
40/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 2/5 criteria met.

  • ❌ Price trend failed
  • ⚠️ Mixed growth
  • ✅ Debt passed
  • ✅ P/E passed
  • ❌ Correction failed

Price trend

Overall trend (8 years): insufficient progression (less than x1.5).

Price change 2018 → 2019: -34.09%

Price change 2019 → 2020: -47.02%

Price change 2020 → 2021: 31.36%

Price change 2021 → 2022: -50.45%

Price change 2022 → 2023: -60.91%

Price change 2023 → 2024: 33.72%

Price change 2024 → 2025: 0.43%

Price change 2025 → 2026: -43.29%

Price change 2026 (year to date): -44.73%

Financial growth

Revenue CAGR (8 years): 54.33%

Earnings CAGR (8 years): N/A

Growth status: positive trend (>1%/yr) in revenue, earnings data insufficient/N/A.

Debt

Debt-to-equity ratio: 0.03

Debt/equity < 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: 2.29

P/E < 25.0 (maximum threshold).

Correction (6 months)

Current correction: 39.63% from the high over 6 months.

Excessive correction (> 20.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, model verdict (buy, watch, sell) and details of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
OrganiGram Holdings Inc.2.10.03–🔒
Bastide Le Confort Médical S.A.21.55.70+10.3 %–
Onward Medical N.V.–0.25+34.5 %–
Guerbet S.A.–1.64+5.5 %–
Euroapi S.A.–0.08−1.3 %–

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Key reported figures

Revenue, net income and net margin reported by Organigram Global Inc. over the latest fiscal years.

Revenue
182 m USD
fiscal year 2025
Net income
-17.4 m USD
fiscal year 2025
Net margin
-9.6 %
fiscal year 2025
Average annual growth
+24.5 %
Revenue growth over 5 years
Average annual growth
+74.6 %
Revenue growth over 10 years
Market cap
117 m USD
Fiscal yearRevenueNet incomeNet marginRevenue growth
202060.8 m-95.4 m-156.9 %n/a
202155.5 m-91.6 m-165.1 %-8.8 %
2022102 m-10.0 m-9.8 %+84.2 %
2023105 m-161 m-153.8 %+2.3 %
2024112 m-31.8 m-28.4 %+7.1 %
2025182 m-17.4 m-9.6 %+62.2 %

Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.

+

Accounts and financial health

Balance sheet and cash flow published by Organigram Global Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).

Overview
average accounts
according to Altman Z, Piotroski and net debt
Altman Z-score
-0.11
risk zone (below 1.81)
Piotroski Score
5 / 9
4 to 6: average accounts
Net Debt / EBITDA
-0.73 x
net cash
Fiscal year20212022202320242025
Cash and investments184 m98.9 m33.9 m108 m84.4 m
Total Debt5.0 m3.4 m4.7 m4.5 m8.8 m
Net Debt-50.4 m-65.2 m-29.1 m-102 m-74.8 m
Equity480 m508 m272 m306 m349 m
Total assets554 m577 m298 m408 m562 m
Operating cash flow-28.6 m-36.2 m-35.8 m3.9 m-6.0 m
Investments (capex)12.3 m48.8 m30.4 m5.3 m17.0 m
Free cash-flow-40.9 m-85.0 m-62.7 m-1.5 m-24.6 m
Share buybacks00000
Dividends paid00000

Amounts in CAD, currency of the published accounts.

Trailing 12-month ratios

Price / earnings (P/E)1.85 x
Price / book value0.33 x
Return on Equity (ROE)22.0 %
Return on Invested Capital (ROIC)-13.7 %
Net margin28.0 %
Debt / equity0.06 x
Current ratio2.61 x
Interest coverage-181.96 x
Free cash-flow yield-17.3 %

Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 16/11/2026.

+

Valuation and competitors

Organigram Global Inc. compared with its sector on the same exchange and with its main competitors.

Company P/E
2.0

Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 13/11/2026. Competitors: comparable companies named by the data provider.

+

Analyst consensus and forecasts

What the financial analysts covering Organigram Global Inc. publish: ratings, price targets and earnings forecasts.

Majority rating
buy
5 analysts

Breakdown of ratings

strong buy 0buy 2hold 2sell 1strong sell 0

Price targets: published for companies listed in the United States only.

Track record against expectations: reported EPS above consensus 6 times over the last 12 releases.

Source: ratings and forecasts published by analysts, collected on 14/11/2026. An analyst rating or target is not a guarantee.

+

Dividends and earnings

Organigram Global Inc.: dividend history, last distributions, stock splits and earnings releases.

No known dividend for this company.

Earnings releases

Next release: 15/12/2026. Expected EPS: 0.01.

DatePublished EPSExpected EPSSurprise
11/08/20260.74-0.01n/a
12/05/2026-0.01-0.01n/a
10/02/20260.15-0.01n/a
16/12/2025-0.28-0.01n/a
13/08/2025-0.05-0.01n/a
12/05/20250.32-0.04n/a

Stock splits

DateOperation
07/07/2023reverse split: 1 share for 4
25/08/2014reverse split: 883 share for 1,000

Factual data: ex-dividend history and earnings calendar, as of 15/11/2026. A past dividend does not guarantee the next one.

+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
Toronto Stock Exchange
IPO: 05/01/2012
ISIN code
CA68620P7056
Workforce
1,093
full-time employees
Chief executive
Beena G. Goldenberg
Next earnings
15/12/2026

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about Organigram Global Inc.

What is the Organigram Global Inc. share price?

Latest recorded price: 1.18 CAD on 13/11/2026, for a market cap of 117 m USD.

What is the revenue of Organigram Global Inc.?

182 m USD for fiscal year 2025, with net income of -17.4 m USD (net margin -9.6 %).

When does Organigram Global Inc. report its next earnings?

The next release is expected on 15/12/2026. EPS expected by analysts: 0.01.

What do analysts say about Organigram Global Inc.?

Out of 5 analysts: 2 buy or strong buy, 2 hold, 1 sell or strong sell.

What is the P/E ratio of Organigram Global Inc.?

Trailing 12-month P/E of 2.0.

Is Organigram Global Inc. stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN CA68620P7056).

How many employees does Organigram Global Inc. have?

1,093 full-time employees according to the latest published profile.

Who runs Organigram Global Inc.?

Beena G. Goldenberg is the company's chief executive.

07

Similar stocks